Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program

Strengthens clinical and regulatory guidance as PSX-001 advances to its next phase of developmentMELBOURNE, Australia and NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces the formation of a Clinical Advisory Board (CAB) to support the continued advancement of its PSX-001 development program in generalized anxiety disorder. The newly established CAB has been formed to provide ...